ARTICLE

Detection, staging and surveillance in renal cell carcinoma

Isaac R Francis

Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA

Corresponding address: Isaac R Francis, MB, BS, Department of Radiology, Box 30, University of Michigan Hospitals, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0030, USA. E-mail: ifrancis@umich.edu

Date accepted for publication 23 August 2006

Abstract

This article discusses the computed tomography (CT) and magnetic resonance (MR) scanning techniques used for the detection and staging of renal cell carcinoma and their pitfalls. Comparison between the Robson and recent modifications to the TNM classifications is also addressed. The accuracy of CT and MR in the staging of renal cell carcinoma and the role of positron emission tomography (PET) scanning is outlined and finally the surveillance of patients who have had curative treatment of renal cell carcinoma is briefly addressed.

Keywords: Kidney: CT techniques; kidney: MR techniques; kidney neoplasms: CT; kidney neoplasms: MR; kidney neoplasms: staging; positron emission tomography (PET).

Introduction

Renal cell carcinoma is the most common primary tumor of the renal parenchyma accounting for 85–90% of solid renal tumors in adults, with approximately 31 200 new cases diagnosed annually in the United States in 2000[1–3]. With the widespread use of cross sectional imaging techniques, the detection of asymptomatic renal cell carcinomas has risen sharply. These incidental tumors are usually smaller in size, with lower tumor stage, and nuclear grade, with improved survival rates, compared to symptomatic tumors. In addition, 5-year survival rates improved from 45% in the 1970s to around 61% in the 1990s. Lead time and length time biases due to earlier detection account in part for this improved survival[4–6].

Scanning techniques

Computed tomography (CT)

The CT scanning technique that is most widely used for renal mass evaluation consists of unenhanced images, followed by images after iodinated intravenous contrast administration. The nephrographic phase of contrast administration, is the most sensitive phase for tumor detection[7,8]. Some centers include arterial and corticomedullary phases of imaging as well, as they are useful for assessing tumor vascularity and for performing 3D image reconstructions[9,10]. Scanning the kidneys in the early phases (arterial and corticomedullary) only has been shown in several studies to result in both false positive and false negative interpretations (Figs 1(A) and (B))[7,8].

Magnetic resonance (MR)

A combination of unenhanced breath-held T1 and T2-weighted images, with chemical shift and fat suppression followed by 3D breath-hold fat-suppressed gadolinium-enhanced T1-weighted sequences at multiple time points during and after contrast administration are essential for the diagnosis and staging of renal cell carcinoma[11–13].

Types of renal cell carcinoma

There are five main types of renal cell carcinoma, the most common being the clear cell type[14]. Papillary
cancers are the next most common: chromophobe cancers have the best prognosis; collecting duct tumors (Bellini’s) and medullary cancers are rare.

**Hereditary renal cancers**

There are various renal cancers that are hereditary[15]. Families with von Hippel–Lindau disease and tuberous sclerosis tend to get clear cell cancers, whereas in the Birt–Hogg Dube syndrome, the tumors tend to be of the chromophobe type. Medullary carcinomas and papillary cancers can also be hereditary. In patients with hereditary leiomyomas, renal papillary cancers can occur.

**Staging**

The two most common staging systems that have been used for renal cell cancer staging are the Robson and TNM classification. Tumor staging for renal cell carcinoma has been incorporated into the TNM system of the UICC in 1997, which has been modified in 2002 (Table 1). The tumor stage is the most important factor affecting the prognosis and survival rate. Tumor type also affects survival, with aggressive anaplastic renal cell carcinomas having a worse prognosis compared to clear cell carcinoma[16–19].

In patients with organ-confined disease, the 5-year survival rate is between 60% and 90% but falls to between 5% and 10% in those with distant metastases.

The role of preoperative imaging is to define the tumor, detect and delineate the extent of venous involvement if any, as well detect the presence of local and distant metastases.

**Tumors confined to the renal parenchyma**

Tumors confined to the renal parenchyma can be either T1 or T2 based on size (T1 ≤ 7 cm and T2 ≥ 7 cm). T1 tumors were recently sub-classified into T1a for tumors <4 cm and T1b for tumors between 4 and 7 cm. Previous studies have shown that CT tends to understage renal cancers as subtle perinephric extension goes undetected. However in a study by Catalano et al.[20] who studied 40 patients with renal cancer using multidetector CT
Figure 3  Coronal T1 and coronal contrast-enhanced gradient echo image after gadolinium enhancement shows well defined renal mass arising from the lower pole of the right kidney. No perinephric extension (T1) lesion was diagnosed at imaging and confirmed at surgery and pathology.

Figure 4  There is no perinephric stranding seen extending from this large mass in the lower pole of the left kidney, placing it as a T2 tumor, but at pathology perinephric extension was confirmed, upstaging this tumor to T3.

(MDCT), all patients with Stage I disease were correctly diagnosed, with only one patient with subtle perinephric extension being understaged (Figs 2 and 3(A) and (B)).

Perinephric extension

In prior studies, it has been shown that imaging using CT and MR had low accuracy rates for the detection of perinephric tumor extension, as stranding in the perinephric fat is non-specific and can be due to many non-neoplastic causes.

Table 1  TNM classification and staging system of renal cell carcinoma (UICC, 2002)

| T-classification | Description                                      |
|------------------|--------------------------------------------------|
| T1               | Confined to kidney, T1a < 4 cm, T1b < 7 cm       |
| T2               | Confined to kidney, >7 cm                         |
| T3a              | Extending to ipsilateral adrenal or perirenal fat |
| T3b              | Extending to renal vein or IVC below diaphragm    |
| T3c              | Extending to IVC above diaphragm                  |
| T4               | Extending beyond Gerota’s fascia                  |
| N-classification |                                                  |
| N0               | No regional lymph node metastasis                |
| N1               | Metastasis in one regional lymph node            |
| N2               | Metastasis in more than one regional lymph node  |
| Nx               | Regional lymph nodes cannot be evaluated         |
| M-classification |                                                  |
| M0               | No distant metastasis                            |
| M1               | Distant metastasis                               |
| Mx               | Distant metastasis cannot be evaluated           |

Stage I: T1 N0 M0
Stage II: T2 N0 M0
Stage III: T3 N0 M0
Stage IV: T4 N0, N1 M0

More recently Catalano et al.\cite{20} showed that MDCT had 95% accuracy for perinephric tumor infiltration with a sensitivity of 96% and specificity of 93% (Figs 4 and 5(A) and (B)).

Venous involvement

Approximately 23% of renal cell carcinomas invade the renal veins and 7% invade the inferior vena cava. The presence and superior extent of tumor thrombus are
essential to plan the surgical approach, as the detection of supradiaphragmatic extension will require a thoraco-abdominal surgical approach[21].

In a recent study of 23 patients with suspected IVC thrombus, the accuracy of MDCT and MR in detecting the extent of thrombus, were compared by Hallscheidt et al.[22]. In this study both modalities were equally accurate (72–88%).

MRI is the most common modality used to define the presence and extent of tumor thrombus, as it is not only reliable in defining extent, but can also differentiate between bland and malignant thrombus (Fig. 6(A) and (B)).

In a study of a small number of patients by Sohaib et al.[23] MRI had a specificity of 89% and accuracy of 94% for detecting transmural invasion by tumor. The most reliable sign for IVC wall invasion in this study was the presence of tumor on either side of the IVC wall (transmural extension).

**Nodal metastases**

Lymph node metastases occur in about 15% of patients in the absence of other metastases[24,25]. Lymph node positivity rate increases in the more advanced T tumors: being about 13% in T1–T3 tumors but increasing to 37% in T4 tumors. The overall 5-year survival rates for tumors that do not have nodal or venous involvement is 43–100%, in contrast to 8–35% for tumors with nodal involvement.
CT and MR have in the past been insensitive to detect nodal metastases in normal-sized nodes. False negative rates of about 10% have been reported using a cut-off in node size of 10 mm (Figs 7 and 8(A) and (B)). More importantly false positive rates of up to 58% due to reactive hyperplasia have been reported. In a recent study by Catalano et al. [20], using MDCT, the authors had very high accuracy with 13/14 true positive cases for nodal metastases.

MR lymphography using ultrasmall iron oxide particles has been shown recently to have very high specificity for nodal metastases in small sub-centimeter nodes [26]. In a study of 80 patients with prostate cancer, Harisinghani et al. [27] have shown that using this technique, sensitivity improved from 35.4% to 90.5% and specificity from 90.4% to 97.8% for pelvic nodal metastases detection. Forty-five of 63 nodes did not meet size criteria for malignancy, but were accurately characterized by lymph node MRI.

Ipsilateral adrenal gland involvement

Overall incidence of adrenal metastases is between 1.2% and 8.5%, being about 1% in T1–T2 tumors. CT with normal appearing adrenal glands has a high negative predictive value for adrenal involvement with metastases, but a positive CT is not always due to malignancy, as adrenal adenomas are more commonly seen even in patients with underlying extra-adrenal malignancy [28–30].

Overall staging accuracy of MR vs. CT

In a study of 82 renal cell carcinomas, by Hallscheidt et al. [31] MDCT and MR were equivalent in the overall
staging of renal cell carcinoma. In this study, overall accuracy for two readers was 83% and 80% for CT compared to 87% and 78% for MRI. Overall accuracy for both modalities and both readers was 80% for all tumors and 85% for T1 tumors.

**Role of fluorodeoxyglucose (FDG)-positron emission tomography (PET)**

PET is not very accurate in distinguishing a renal cell carcinoma from other solid renal neoplasms and is therefore not used in the initial workup of a solid renal mass. But it appears moderately useful in the detection of metastatic disease (Fig. 9(A) and (B)) and local recurrence.

**Surveillance following nephrectomy**

In a recent study of 194 patients, Chae et al.\cite{Chae2003} reported an incidence of recurrence or metastases in 21%, with common sites being lung, bone, the nephrectomy bed and the liver. Tumor recurrence was seen within 2 years in over 80% of patients, the mean time to recurrence being 17 months. More advanced stage tumors with higher nuclear Fuhrman grade were more likely to recur or metastasize\cite{Ficarra2003}.

In most centers in the United States no systematic follow up regimen is universally accepted. In one center, for T1 and T2 tumors, annual chest X-rays are performed; with 6 monthly chest X-rays for 3 years; CT of the abdomen is performed at 6, 12, 24 and 36 months for T3 and T4 tumors\cite{Volpe2004}. The European Association of Urology has adopted a guideline which uses CT as an optional exam for all T1 and T2 tumors and T3 and T4 tumors only after year 3\cite{Urban2004}.

**References**

1. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. Radiographics 2001; 21: S237–54.
2. Israel GM, Bosniak MA. Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am 2003; 30: 499–514.
3. American Cancer Society. Cancer Facts and Figures 2000. Atlanta, GA: American Cancer Society, 2000: p. 4.
4. Tsui KH, Shvarts O, Smith RB et al. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163: 426–30.
5. Ficarra V, Prayer-Galetti T, Novella G et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 2003; 43: 663–9.
6. Volpe A, Panzarella T, Rendon RA et al. The natural history of incidentally detected small renal masses. Cancer 2004; 15: 738–45.
7. Yuh BI, Cohan RH, Francis IR et al. Comparison of nephrographic with excretory phase image helical computed tomography for detecting and characterizing renal masses. J Can Assoc Radiol 2000; 51: 170–6.
8. Dahlman P, Semenas E, Bergman A et al. Detection and characterization of renal lesions using multiphasic CT. Acta Radiol 2000; 41: 361–6.
9. Coll DM, Herts BR, Davros WJ et al. Pre-operative use of 3D volume rendering to demonstrate renal tumors and renal anatomy. Radiographics 2000; 20: 431–8.
10. Urban BA, Ratiner LE, Fishman EK. Three-dimensional volume-rendered CT angiography of the renal arteries and veins: normal anatomy, veins, and clinical applications. Radiographics 2001; 21: 373–86.
11. Ergen FB, Hussain HK, Caoli EM et al. MRFI for preoperative staging of renal cell carcinoma using the 1999 TNM classification: comparison with surgical and pathological staging. AJR 2004; 182: 217–25.
12. Kamel IR, Hochman MG, Keogan MT et al. Accuracy of breath-
hold magnetic resonance imaging in preoperative staging of organ-confined renal cell carcinoma. J Comput Assist Tomogr 2004; 28: 327–32.

[13] Huang GJ, Israel G, Berman A et al. Preoperative renal tumor evaluation by three-dimensional magnetic resonance imaging: staging and detection of multifocality. Urology 2004; 64: 451–7.

[14] Kim JK, Kim TK, Ahn KJ, Kim CS, Kim KR, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. Am J Roentgenol 2002; 178: 1499–506.

[15] Choyke PL, Glenn GM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology 2003; 226: 33–46.

[16] Fleming ID, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven, 1997.

[17] Minervini R, Minervini A, Fontana N, Traversi C, Cristofani R. Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: experience in 172 patients. BJU International 2000; 86(3): 199–202.

[18] Pode D. Renal cell carcinoma: evaluation of the 1997 TNM staging system. Cancer 2001; 91: 354–61.

[19] Gofrit ON, Shapiro A, Kovalski N, Landau EH, Shenfeld OZ, Pode D. Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery. European Urology 2001; 29: 669–75.

[20] Catalano C, Fraioli F, Laghi A et al. High-resolution multidetector CT in the preoperative evaluation of patients with renal cell carcinoma. Am J Roentgenol 2003; 180: 1271–7.

[21] Laissy JP, Menegazzo D, Debry MP et al. Renal carcinoma: diagnosis of venous invasion with Gd-enhanced MR venography. Eur Radiol 2000; 10: 1138–43.

[22] Ballscheidt PJ, Fink C, Haferkamp A et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr 2005; 29: 64–8.

[23] Aslam Sohab SA, Teh J, Nargund VH, Lumsley IS, Hendry WF, Reznik RH. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging. J Urol 2002; 167: 1271–6.

[24] Studer UE, Scherz S, Scheidegger J et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144: 243–5.

[25] Herrlinger A, Schrott KM, Schott G et al. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma? J Urol 1991; 146: 1224–7.

[26] Saokar A, Braschi M, Harisinghani M. Lymphotrophic nanoparticle-enhanced MR imaging (LNMRI) for lymph node imaging. Abdominal Imaging 2006; May 6 [E-pub ahead of print].

[27] Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491–9.

[28] Gill IS, McClennan BL, Kerbl K et al. Adrenal involvement from renal cell carcinoma: Predictive value of computerized tomography. J Urol 1994; 152: 1082–5.

[29] Tsai KH, Shvarts O, Barbaric Z, Figlin R, de Kernion JB, Belldegrun A. Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol 2000; 163: 437–41.

[30] Antonino R, Di Lorenzo C, Damiano R et al. Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible? World J Urol 2003; 21: 153–8.

[31] Ballscheidt PJ, Bock M, Riedlasch G et al. Diagnostic accuracy of staging renal cell carcinoma using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathological correlation. J Comput Assist Tomogr 2004; 28: 333–9.

[32] Ramdave S, Thomas GW, Berlangieri SU et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 155(3): 825–30.

[33] Majhail N, Urbain JL, Albani J et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 221: 3995–4000.

[34] Chae EJ, Kim JK, Kim SH, Bae SJ, Cho KS. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 2005; 234: 189–96.

[35] Scatarige JC, Sheth S, Corl FM, Fishman EK. Patterns of recurrence in renal cell carcinoma: manifestations on helical CT. AJR 2001; 177(3): 653–8.

[36] Stephenson AJ, Chetner MP, Rourke K et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 2004; 172: 58–62.

[37] Said JI, Newhouse JH, Sawczuk IS. Radiologic follow-up of patients with T1–3a, b, c or T4N+M0 renal cell carcinoma after radical nephrectomy. J Urol 1995; 52: 1000–3.

[38] Mickisch G, Carballido J, Hellsten S et al. Guidelines on renal cell cancer. Eur Urol 2001; 40: 252–5.